CA Patent

CA2892445C — Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Assigned to Geron Corp · Expires 2022-06-28 · 4y expired

What this patent protects

Provided herein are methods for identifying individuals diagnosed with a cell proliferative disorder that will benefit from treatment with a telomerase inhibitor compound. Also provided herein are methods for treating these individuals with telomerase inhibitor compounds. The met…

USPTO Abstract

Provided herein are methods for identifying individuals diagnosed with a cell proliferative disorder that will benefit from treatment with a telomerase inhibitor compound. Also provided herein are methods for treating these individuals with telomerase inhibitor compounds. The methods comprise identifying individuals who will benefit from said treatment based on the average relative length of telomeres in cancer cells from said individuals.

Drugs covered by this patent

Patent Metadata

Patent number
CA2892445C
Jurisdiction
CA
Classification
—
Expires
2022-06-28
Drug substance claim
No
Drug product claim
No
Assignee
Geron Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.